NASDAQ$MLTX
MoonLake Immunotherapeutics · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
MoonLake Immunotherapeutics reported its financial results for the second quarter of 2024, showing increased operating expenses and a larger net loss compared to the prior year.
The company continued its clinical development of sonelokimab with higher research and development spending. Cash and short-term investments remained strong at over $519 million. The net loss widened to $24.8 million for the quarter due to expanded clinical activities.
- R&D expenses rose to $23.7 million, driven by Phase 3 trial initiations in HS and other programs.
- Net loss increased to $24.8 million from $12.4 million in Q2 2023.
- Cash, cash equivalents and short-term marketable securities totaled $519.8 million at quarter end.
- The company remains pre-revenue with operating expenses focused on advancing SLK through clinical trials.
Headline financials
Revenue & EPS history
MoonLake · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports
+0.3%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+7.7%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+23.1%
Q2 2022
Best reaction
-10.4%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q2 2025 | +0.2% | — | — | |
| Q4 2026 | +0.2% | -2.9% | -4.8% | |
| Q3 2025 | -2.8% | +11.0% | +40.7% | |
| Q1 2025 | +4.7% | -2.2% | +14.8% | |
| Q4 2024 | -4.5% | -2.5% | -2.1% | |
| Q3 2024 | +0.6% | +0.8% | +5.5% | |
| Q1 2024 | -4.2% | -8.1% | -4.7% | |
| Q4 2023 | -10.4% | -15.3% | -11.6% | |
| Q3 2023 | +7.1% | +16.6% | +57.3% | |
| Q2 2023 | +3.5% | +3.8% | -5.7% | |
| Q1 2023 | +0.2% | +5.5% | +9.6% | |
| Q4 2022 | -4.9% | -9.2% | -5.6% | |
| Q3 2022 | -0.1% | -5.4% | +4.0% | |
| Q2 2022 | +23.1% | +45.8% | +33.0% | |
| Q1 2022 | -6.1% | +4.3% | +2.6% | |
| Q2 2021 | -0.1% | +0.0% | -0.1% | |
| Q4 2021 | -0.1% | +0.0% | -0.1% | |
| Q3 2021 | -1.3% | -1.3% | -1.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro